FDA Approves Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Early-Stage NSCLC
Efficacy was evaluated in CHECKMATE-816 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
German National Network Genomic Medicine Suggests a Novel Classification of Atypical EGFR Mutations
Classifications is proposed according sensitivity of atypical EGFR mutations to tyrosine kinase inhibitors
EMA Recommends Extension of Therapeutic Indications for Abemaciclib
New indication concerns the use in patients with early breast cancer at high risk of recurrence
Addition of a Live Bacterial Product Enhances the Clinical Outcome in Patients with mRCC Treated with Nivolumab-Ipilimumab Combination
Promising clinical benefit associated with an enrichment of bacterial species, circulating cytokines and immune cell populations in responders
No Impact on Survival from Dose Reduction and Interruption for the Management of Olaparib Associated Adverse Events
SOLO2 ancillary study findings will help assure patients that their outcomes will not be adversely affected when dose reductions or interruptions are needed
EMA Recommends Extension of Therapeutic Indications for Nivolumab
New indications concern the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma and the adjuvant treatment of muscle invasive urothelial carcinoma
Humoral Response to the Third Dose of the mRNA-based COVID-19 Vaccine in a Large Cohort of Patients with Cancer
Most patients were on active anticancer treatment during the 28 days before the administration of third dose
Lung Metastases, Cytoreductive Nephrectomy and Favourable Risk Group Associated with a Higher Probability of Response to First-Line Combination Therapy in mRCC
Findings from the international metastatic renal cell database consortium
EMA Recommends Granting a Marketing Authorisation for Stimufend
Stimufend is a biosimilar, highly similar to the reference product Neulasta (pegfilgrastim), which was authorised in the EU in 2002
Adding Darolutamide to ADT and Docetaxel Prolongs Overall Survival in Patients with Metastatic, Hormone-Sensitive Prostate Cancer
Improvements also observed with respect to key secondary endpoints, with no increase in adverse events
Higher Risk of Major Adverse Cardiovascular Events and Cancers with Tofacitinib
EMA starts safety review of Janus kinase inhibitors used for inflammatory disorders
Cancer Mortality Predictions for the 10 Major Causes of Cancer Mortality and Total Cancer in 2022 in the European Union
Additional declines in cancer mortality rates predicted for 2022